| Drug Name |
Posaconazole |
| Drug ID |
BADD_D01804 |
| Description |
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. |
| Indications and Usage |
For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals. |
| Marketing Status |
approved; investigational; vet_approved |
| ATC Code |
J02AC04 |
| DrugBank ID |
DB01263
|
| KEGG ID |
D02555
|
| MeSH ID |
C101425
|
| PubChem ID |
468595
|
| TTD Drug ID |
D07ABV
|
| NDC Product Code |
14501-0076; 17511-133; 73005-0001; 76397-011; 0254-1016; 70748-258; 12860-0041; 55111-995; 66406-0200; 76397-002; 17856-2133; 31722-677; 43598-470; 0406-7711; 70377-038; 0527-2133; 16714-156; 0085-4331; 42291-919; 60687-523; 76397-024; 14501-0067; 0904-7149; 62227-010; 76397-023; 0085-1328; 0085-4324; 16714-535; 42023-195; 51407-676; 69037-0020; 69367-248; 12860-0133; 65727-059; 58032-1017; 62227-008; 0085-2224; 63629-2236; 69238-1476; 0054-0449; 42765-020; 62227-001; 50268-683; 0254-2045 |
| UNII |
6TK1G07BHZ
|
| Synonyms |
posaconazole | 4-(p-(4-(p-(((3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one | Noxafil | SCH-56592 | SCH 56592 | posaconazole hydrate |
